Shenzhen Salubris Pharmaceuticals Co Ltd
Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also develops Sacubit… Read more
Shenzhen Salubris Pharmaceuticals Co Ltd (002294) - Total Assets
Latest total assets as of September 2025: CN¥10.98 Billion CNY
Based on the latest financial reports, Shenzhen Salubris Pharmaceuticals Co Ltd (002294) holds total assets worth CN¥10.98 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shenzhen Salubris Pharmaceuticals Co Ltd - Total Assets Trend (2006–2024)
This chart illustrates how Shenzhen Salubris Pharmaceuticals Co Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Shenzhen Salubris Pharmaceuticals Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Shenzhen Salubris Pharmaceuticals Co Ltd's total assets of CN¥10.98 Billion consist of 38.5% current assets and 61.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 10.8% |
| Accounts Receivable | CN¥589.72 Million | 5.6% |
| Inventory | CN¥506.76 Million | 4.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥2.81 Billion | 26.9% |
| Goodwill | CN¥10.91 Million | 0.1% |
Asset Composition Trend (2006–2024)
This chart illustrates how Shenzhen Salubris Pharmaceuticals Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shenzhen Salubris Pharmaceuticals Co Ltd's current assets represent 38.5% of total assets in 2024, a decrease from 71.9% in 2006.
- Cash Position: Cash and equivalents constituted 10.8% of total assets in 2024, up from 4.2% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 26.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is intangible assets at 26.9% of total assets.
Shenzhen Salubris Pharmaceuticals Co Ltd Competitors by Total Assets
Key competitors of Shenzhen Salubris Pharmaceuticals Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Shenzhen Salubris Pharmaceuticals Co Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Shenzhen Salubris Pharmaceuticals Co Ltd generates 0.38x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Shenzhen Salubris Pharmaceuticals Co Ltd generates $5.75 in net profit.
Shenzhen Salubris Pharmaceuticals Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.15 | 3.72 | 1.94 |
| Quick Ratio | 2.78 | 3.24 | 1.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.98 Billion | CN¥ 2.75 Billion | CN¥ 1.03 Billion |
Shenzhen Salubris Pharmaceuticals Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shenzhen Salubris Pharmaceuticals Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.45 |
| Latest Market Cap to Assets Ratio | 0.34 |
| Asset Growth Rate (YoY) | 11.4% |
| Total Assets | CN¥10.47 Billion |
| Market Capitalization | $3.52 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Shenzhen Salubris Pharmaceuticals Co Ltd's assets below their book value (0.34 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Shenzhen Salubris Pharmaceuticals Co Ltd's assets grew by 11.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Shenzhen Salubris Pharmaceuticals Co Ltd (2006–2024)
The table below shows the annual total assets of Shenzhen Salubris Pharmaceuticals Co Ltd from 2006 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥10.47 Billion | +11.38% |
| 2023-12-31 | CN¥9.40 Billion | -3.67% |
| 2022-12-31 | CN¥9.76 Billion | +5.53% |
| 2021-12-31 | CN¥9.24 Billion | +33.61% |
| 2020-12-31 | CN¥6.92 Billion | -10.54% |
| 2019-12-31 | CN¥7.73 Billion | -2.17% |
| 2018-12-31 | CN¥7.90 Billion | +15.16% |
| 2017-12-31 | CN¥6.86 Billion | +5.05% |
| 2016-12-31 | CN¥6.53 Billion | +21.30% |
| 2015-12-31 | CN¥5.39 Billion | +16.70% |
| 2014-12-31 | CN¥4.62 Billion | +26.70% |
| 2013-12-31 | CN¥3.64 Billion | +22.23% |
| 2012-12-31 | CN¥2.98 Billion | +21.90% |
| 2011-12-31 | CN¥2.45 Billion | +12.43% |
| 2010-12-31 | CN¥2.17 Billion | +22.74% |
| 2009-12-31 | CN¥1.77 Billion | +333.66% |
| 2008-12-31 | CN¥408.60 Million | +59.65% |
| 2007-12-31 | CN¥255.94 Million | +61.31% |
| 2006-12-31 | CN¥158.66 Million | -- |